Back to Results
First PageMeta Content
Organofluorides / Alcohols / Aging-associated diseases / Medical emergencies / AstraZeneca / Ticagrelor / Prasugrel / Clopidogrel / Antiplatelet drug / Chemistry / Organic chemistry / Medicine


Addenda to Briefing Document
Add to Reading List

Open Document

File Size: 461,02 KB

Share Result on Facebook

Company

ACS / ASTRAZENECA LP / /

Country

United States / /

Currency

pence / /

Event

FDA Phase / /

IndustryTerm

web response system / /

MedicalCondition

strokes / myocardial infarction / ST segment elevation myocardial infarction / cancer / acute coronary syndromes / myopathy / angina / non-ST segment elevation myocardial infarction / neutropenia / stroke / /

MedicalTreatment

concomitant therapy / /

Organization

FDA / Briefing Document FDA Advisory Committee for Ticagrelor / DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DIVISION OF CARDIOVASCULAR AND RENAL PRODUCTS Date / /

Person

A. Marciniak / THOMAS A MARCINIAK / Thomas A. Marciniak / /

Position

investigator / Major / medical officer / Medical Team Leader / M.D. Medical Team Leader / /

Product

clopidogrel / simvastatin / lovastatin / CYP3A / /

Technology

pharmacokinetics / /

SocialTag